Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival in muscle-invasive bladder cancer. NEOBLADE was a parallel-arm, double-blind, randomised,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2022-05, Vol.23 (5), p.650-658
Hauptverfasser:	Hussain, Syed A, Lester, Jason F, Jackson, Richard, Gornall, Matthew, Qureshi, Muneeb, Elliott, Anthony, Crabb, Simon J, Huddart, Robert A, Vasudev, Naveen, Birtle, Alison J, Worlding, Jane, James, Nicholas D, Parikh, Omi, Vilarino-Varela, Maria, Alonzi, Roberto, Linch, Mark D, Riaz, Irbaz B, Catto, James W F, Powles, Thomas, Jones, Robert J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Arm Bladder cancer Cancer Cancer therapies Chemotherapy Cisplatin Cisplatin - adverse effects Clinical trials Deoxycytidine - analogs & derivatives Double-Blind Method Double-blind studies Female Gemcitabine Glomerular filtration rate Humans Indoles Intravenous administration Invasiveness Laboratories Leukocytes (neutrophilic) Lung cancer Lymphatic system Male Metastasis Muscles Myocardial infarction Neoadjuvant Therapy - adverse effects Patients Placebos Radiation therapy Thromboembolism Urinary Bladder Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!